Panelists discuss how decisions to switch between Bruton tyrosine kinase (BTK) inhibitors are driven by multiple factors including intolerable toxicities, development of resistance mutations ...
Video content above is prompted by the following: The ASH abstract by Mansour and colleagues suggests that for patients who have been on BTK inhibitors for more than 2 years, discontinuing therapy ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.
The US regulator has placed oral BTK inhibitor orelabrutinib on partial clinical hold, meaning new patients cannot be enrolled into clinical trials and patients treated with the drug for 70 days ...
Credit: Nadezhda Fedrunova via Getty Images. AstraZeneca has received approval from the US Food and Drug Administration (FDA) for its Bruton’s tyrosine kinase (BTK) inhibitor, Calquence (acalabrutinib ...
AstraZeneca’s Calquence became the first BTK inhibitor approved in the US for first-line use in mantle cell lymphoma on Thursday. The drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback